Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Cardiovascular risk in patients with type 2 diabetes

Miriam Shanks, Daniel T. Holmes, Luba Cermakova and Jiri Frohlich
CMAJ April 26, 2005 172 (9) 1160-1161; DOI: https://doi.org/10.1503/cmaj.1050049
Miriam Shanks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel T. Holmes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luba Cermakova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiri Frohlich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading
  • © 2005 CMA Media Inc. or its licensors

Lauren Brown and associates1 observed low use of therapies with proven benefit for the prevention of cardiovascular events in patients with type 2 diabetes, both with and without atherosclerotic disease. We are conducting a similar study analyzing use of acetylsalicylic acid (ASA), statins, β-blockers and angiotensin-converting enzyme (ACE) inhibitors (or equivalent) in a cohort of 407 high-risk patients attending the Lipid/Cardiovascular Risk Reduction Clinic at St. Paul's Hospital in Vancouver. These patients have a history of vascular disease (coronary, peripheral or cerebral) with or without diabetes.

Data on the patients' lipid profile and use of the 4 medications at the time of the initial visit to the clinic (between 1984 and 2004) and their most recent visit (between November 2003 and July 2004) have been collected (Table 1). The use of these medications will also be prospectively evaluated at the next scheduled visit.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1.

We are also trying to examine differences in medication use in a subgroup of 178 patients with diabetes from the same cohort: 54 with established coronary artery disease (CAD) and 124 without clinical evidence of CAD. Preliminary data were obtained from the most recent follow-up visits (with an average of 60 months between the first and the most recent visit). We found no significant differences in the use of ASA and statins between the 2 groups; however, the rate of treatment with β-blockers and ACE inhibitors was significantly higher among patients with CAD than among those without CAD. Although the difference in β-blocker use was not unexpected, we were surprised by the low use of ACE inhibitors or equivalent for patients who had diabetes but no clinical evidence of CAD.

These preliminary results indicate that there is room for improvement in implementing treatment guidelines in clinical practice. The overall use of cardioprotective medications was suboptimal at the initial visit, although use had increased significantly by the time of the most recent visit (Table 1). However, the use of ACE inhibitors remained suboptimal among diabetic patients without CAD, a result similar to the data presented by Brown and associates.1 We agree that multidisciplinary cardiovascular risk reduction programs are needed to improve quality of care in high-risk patients.

Footnotes

  • Competing interests: None declared.

Reference

  1. 1.↵
    Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004;171(10):1189-92.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 172 (9)
CMAJ
Vol. 172, Issue 9
26 Apr 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cardiovascular risk in patients with type 2 diabetes
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cardiovascular risk in patients with type 2 diabetes
Miriam Shanks, Daniel T. Holmes, Luba Cermakova, Jiri Frohlich
CMAJ Apr 2005, 172 (9) 1160-1161; DOI: 10.1503/cmaj.1050049

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Cardiovascular risk in patients with type 2 diabetes
Miriam Shanks, Daniel T. Holmes, Luba Cermakova, Jiri Frohlich
CMAJ Apr 2005, 172 (9) 1160-1161; DOI: 10.1503/cmaj.1050049
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • Reference
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Responding to Bill C-7
  • Benefits of nirmatrelvir–ritonavir remain unproven for some populations
  • Renalism
Show more Letters

Similar Articles

Collections

  • Topics
    • Diabetes

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers
  • CPD credits

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire